Selinexor plus R-CHOP for first-line treatment of TP53-mutated DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests adding selinexor to the standard R-CHOP chemotherapy for people with a specific type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better as the first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with DLBCL that has a TP53 gene mutation.
- You have not received any prior chemotherapy for lymphoma (previous localized radiation is okay).
- You have at least one tumor that can be measured on scans.
- You are in reasonably good health (able to care for yourself, adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the drug selinexor to a standard high-dose chemotherapy regimen (BEAM) before an autologous stem cell transplant for people with MYC-positive diffuse large B-cell lymphoma that has returned or not responded to prior treatments. The goal is to see if this combination is safe and effective in preparing the body for the transplant.
This study tests whether adding a drug called selinexor to a standard chemo-immunotherapy combination (called R-GDP) can help people whose large B-cell lymphoma has a TP53 gene change and has not responded to earlier treatment. The goal is to see if this combination helps control the lymphoma.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
This Phase 2 study tests whether a medicine called selinexor, combined with COPL, can shrink newly diagnosed NK/T-cell lymphoma that is advanced (stage III–IV). It also looks at how safely the treatment works in people who have good enough blood counts and organ function.
This trial tests a new drug called Purinostat Mesylate for people with diffuse large B-cell lymphoma (a type of blood cancer) whose cancer has come back or not responded after at least two prior treatments. It aims to see if the drug can help shrink or control the cancer.
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.